Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBIT Margin (2016 - 2025)

Ironwood Pharmaceuticals' EBIT Margin history spans 16 years, with the latest figure at 161.38% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 19616.0% year-over-year to 161.38%; the TTM value through Dec 2025 reached 4.97%, down 2153.0%, while the annual FY2025 figure was 4.97%, 2153.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 161.38% at Ironwood Pharmaceuticals, down from 61.84% in the prior quarter.
  • Across five years, EBIT Margin topped out at 666.87% in Q4 2023 and bottomed at 1008.68% in Q2 2023.
  • The 5-year median for EBIT Margin is 52.13% (2021), against an average of 10.31%.
  • The largest annual shift saw EBIT Margin tumbled -106592bps in 2023 before it surged 103514bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 48.32% in 2021, then skyrocketed by 32bps to 63.77% in 2022, then surged by 946bps to 666.87% in 2023, then plummeted by -95bps to 34.78% in 2024, then tumbled by -564bps to 161.38% in 2025.
  • Per Business Quant, the three most recent readings for IRWD's EBIT Margin are 161.38% (Q4 2025), 61.84% (Q3 2025), and 53.17% (Q2 2025).